This article includes recommendations for management of most sexually transmitted infections (STIs) other than HIV and viral hepatitis. Some of the indications and dosages recommended here have not been approved by the FDA (see Table 1).
PARTNER TREATMENT — Management of all STIs should include evaluation of recent sex partners of infected persons. If possible, partners should be examined and tested for STIs, but in most cases partner treatment of bacterial STIs and trichomoniasis should be started regardless of symptoms...
- Mavacamten (Camzyos) for Obstructive Hypertrophic Cardiomyopathy
- Tenapanor (Ibsrela) for Irritable Bowel Syndrome with Constipation
- COVID-19 Update: Booster Dose of the Pfizer Vaccine for Children 5-11 Years Old
- COVID-19 Update: FDA Narrows EUA for the Johnson & Johnson Vaccine
- COVID-19 Update: NIH Recommends Against Ivermectin
- COVID-19 Update: Remdesivir (Veklury) FDA-Approved for Children <12 Years Old (online only)
- COVID-19 Update: Baricitinib (Olumiant) FDA-Approved for Treatment of COVID-19 (online only)
The FDA has approved Vtama (Dermavant), a 1% cream formulation of the aryl hydrocarbon receptor (AhR) agonist tapinarof, for treatment of adults with plaque psoriasis. It is the first AhR agonist to be approved by the FDA.
TOPICAL TREATMENT ― Topical corticosteroids are generally used for initial treatment of mild to moderate plaque psoriasis. The topical retinoid tazarotene or a topical vitamin D analog such as calcipotriene or calcitriol …